Fig. 6. Chemogenomic screen. To identify potential drug targets the pool of tagged 5936 S. cerevisiae heterozygous deletion mutants was grown competitively for 20 generations in the presence and absence of compound 2a. Strain fitness was determined via high-throughput barcode sequencing and normalization to the untreated control. log 2 ratio (control intensity/treatment intensity) was calculated and plotted as a function of gene. The genome-wide readout of heterozygous mutants highly sensitive to compound 2a included the known target of azoles, ERG11 and novel targets such as the RAN GTPase GSP1 (red dots: log FC > 1.5 and P value >0.01).